Introduction {#s1}
============

Tissue damage results in an accumulation of endogenous chemical substances, such as bradykinin (BK), which are released by nociceptive afferents and/or non-neural cells in the injured area of the tissue (Julius and Basbaum, [@B15]; Basbaum et al., [@B3]). BK receptors, which are divided into two subtypes (B~1~ and B~2~), are plasma membrane G-protein-coupled receptors of the seven-transmembrane-domain family. The existence of B~1~ and B~2~ receptors has been confirmed by pharmacological and radioligand-binding studies, as well as by mRNA expression analyses, in a wide variety of cells (Hess et al., [@B14]; Pesquero et al., [@B26]; Hall, [@B13]). Previous studies have indicated that B~2~ receptors couple with the Gq protein. Activation of the Gq protein activates phospholipase C, which induces a number of intracellular second messenger systems, including 1, 2-diacylglycerol and inositol 1, 4, 5-trisphosphate, which activates protein kinase C and mobilizes intracellular Ca^2+^, respectively (Walker et al., [@B33]; Tiwari et al., [@B32]).

BK-induced changes in the chemical environment surrounding axons cause peripheral sensitization, which is associated with inflammatory responses (Basbaum et al., [@B3]). Neuropathic pain is also involved in peripheral and central sensitization, which increases chronic pain states (Cervero and Laird, [@B7]; Scholz and Woolf, [@B29]; Ochoa, [@B24]). Injury to trigeminal ganglion (TG) neurons, which occasionally induces neuropathic pain, has been reported to be mediated by both B~1~ and B~2~ receptors in the orofacial area. Formalin-induced orofacial pain responses in rats are reduced by B~2~ receptor inhibition (Chichorro et al., [@B8]). In addition, administration of B~1~ and B~2~ receptor antagonists delays the development of thermal hyperalgesia in the orofacial area, which is induced by constriction of the infraorbital nerve in rats and mice (Luiz et al., [@B19]). Thus, the functional role of BK receptors in TG neurons in physiological and pathological nociception has been well described by behavioral studies. However, the basic expression patterns of B~1~ and B~2~ receptors in TG neurons are still unclear and remain to be fully elucidated.

In the present study, we investigated the expression and localization, as well as physiological and pharmacological properties, of B~1~ and B~2~ receptors in primary cultured rat TG neurons.

Materials and Methods {#s2}
=====================

Ethical Approval {#s2-1}
----------------

All the animals used in our study were treated in accordance with the Guiding Principles for the Care and Use of Animals in the Field of Physiological Sciences, which was approved by the Council of the Physiological Society of Japan and the American Physiological Society. In addition, the study followed the guidelines that were established by the National Institutes of Health (USA) regarding the care and use of animals for experimental procedures. This study was approved by the Animal Research Ethics Committee of Tokyo Dental College (approval No. 252502).

Cell Culture {#s2-2}
------------

TG cells were isolated from neonatal Wistar rats (7 days old) (Kawaguchi et al., [@B16]) that were under pentobarbital sodium anesthesia (50 mg/kg) following the administration of isoflurane (3.0 Vol%). TG cells were dissociated by enzymatic treatment with Hank's balanced salt solution (Life Technologies, Grand Island, NY, USA) containing 20 U/mL papain (Worthington Biochemical Corporation, Lakewood, NJ, USA) for 20 min at 37°C, which was followed by dissociation by trituration. After dissociation, the TG cells were plated on 35 mm-diameter dishes (Corning Incorporated Life Sciences, Tewksbury, MA, USA) and cultured for 48 h at 37°C (95% air and 5% CO~2~). The primary cells were cultured in Leibovitz's L-15 medium (Life Technologies) containing 10% fetal bovine serum, 1% penicillin-streptomycin (Life Technologies), 1% fungizone (Life Technologies), 26 mM NaHCO~3~, and 30 mM glucose (pH 7.4). For the immunocytochemistry, TG cells were subjected to primary culture on poly-L-lysine-coated cover glasses (Matsunami Glass Ind., Ltd., Osaka, Japan).

Immunofluorescence Analysis {#s2-3}
---------------------------

TGs isolated from neonatal Wistar rats (7 days old) were fixed in optimal cutting temperature compound and rapidly frozen in liquid nitrogen. Frozen tissues were cut at a thickness of 10 μm and placed on slides. After fixation by 50% ethanol and 50% acetone at −20°C for 30 min, primary cultured TG cells and cryosections were treated with 10% donkey serum at room temperature for 20 min and then incubated overnight at 4°C with primary antibodies (Kuroda et al., [@B18]). A cocktail of primary antibodies (Neuro-Chrom^TM^ Pan Neuronal Marker, EMD Millipore, Billerica, MA, USA; 1:50 dilution), including mouse anti-Neuronal nuclei (NeuN), anti-microtubule-associated protein 2 (MAP2), anti-βIII tubulin, and anti-neurofilament H (NF-H) antibodies, was used as a neuronal marker. TG cells were also incubated with either mouse anti-NF-H (SantaCruz, CA, USA; 1:200 dilution) as an A-neuron marker, mouse anti-substance P (SP; R&D Systems, Minneapolis, MN, USA; 2.5 μg/100 μl dilution) as a peptidergic C-neuron marker, FITC-conjugated anti-isolectin B4 (IB4; Vector laboratories, CA, USA; 1:200 dilution) as a non-peptidergic C-neuron marker, goat anti-high-affinity nerve growth factor (NGF) receptor (a tropomyosin receptor kinase A (TrkA); R&D Systems; 1.5 μg/100 μl dilution) as an NGF-responsive nociceptor marker (Mantyh et al., [@B21]), and rabbit anti-B~1~ receptor (Alomone Labs, Jerusalem, Israel; 1:50 dilution) and rabbit anti-B~2~ receptor (Alomone Labs; 1:50 dilution) (Duehrkop et al., [@B9]; Dutra et al., [@B10]) antibodies. For negative controls, the sections were incubated with non-immune IgGs (Abcam, Cambridge, UK; 1:50; *N* = 4 from four rats) (Figure [](#F1){ref-type="fig"}[2M](#F2){ref-type="fig"}). The cells and tissues were then washed and incubated with a secondary antibody at room temperature for 30 min. The secondary antibodies were Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 568 donkey anti-mouse IgG, Alexa Fluor 568 donkey anti-rabbit IgG, and Alexa Fluor 568 donkey anti-goat IgG (1:50 dilution; Life Technologies) for the fluorescence staining and 4′, 6-diamino 2-phenylindole dihydrochloride (Life Technologies) for the nuclear staining (room temperature for 5 min). The cells and tissues were examined under fluorescence microscopes (Carl Zeiss AG, Jena, Germany; Keyence Corporation, Osaka, Japan).

Solutions and Reagents {#s2-4}
----------------------

A standard solution containing (in mM) 137 NaCl, 5.0 KCl, 2.0 CaCl~2~, 0.5 MgCl~2~, 0.44 KH~2~PO~4~, 0.34 Na~2~HPO~4~, 4.17 NaHCO~3~, and 5.55 glucose (pH 7.4) was used as an extracellular solution. A high-K^+^ solution containing (in mM) 91 NaCl, 50 KCl, 2.0 CaCl~2~, 0.5 MgCl~2~, 0.44 KH~2~PO~4~, 0.34 Na~2~HPO~4~, 4.17 NaHCO~3~, and 5.55 glucose (pH 7.4) was used to discern TG neurons from glial cells by activation of depolarization-induced increases in intracellular free Ca^2+^ concentration (\[Ca^2+^\]~i~) in neurons. BK, a selective B~2~ receptor antagonist (HOE140), a selective B~1~ receptor antagonist (R715) and a highly selective B~1~ receptor agonist (Lys-\[Des-Arg^9^\]BK) were obtained from Tocris Bioscience (Bristol, UK). All the other reagents were purchased from Sigma-Aldrich Co. LLC (St. Louis, MO, USA), except where indicated.

Measurement of \[Ca^2+^\]~i~ {#s2-5}
----------------------------

Primary cultured TG cells were loaded for 90 min at 37°C in Hank's solution containing 10 μM of fura-2 acetoxymethyl ester (Dojindo Laboratories, Kumamoto Japan) and 0.1% (w/v) pluronic acid F-127 (Life Technologies). Cultured TG cells were then rinsed with fresh Hank's solution and mounted on a microscope stage (Olympus Corporation, Tokyo, Japan). Fura-2 fluorescence emission was measured at 510 nm in response to alternating excitation wavelengths of 340 nm (*F*340) and 380 nm (*F*380) with an Aquacosmos system and software (Hamamatsu Photonics K.K., Shizuoka, Japan), which controls the excitation wavelength selector and intensified charge-coupled device camera system (Hamamatsu Photonics K.K.). \[Ca^2+^\]~i~ was measured as the fluorescence ratio of *F*340 and *F*380 (R*~F340/F380~*) and expressed as *F/F*~0~ units. The R*~F340/F380~* value (*F*) was normalized to the resting value (*F*~0~).

Statistical and Offline Analysis {#s2-6}
--------------------------------

The data were expressed as the mean ± standard error (S.E.) or standard deviation of the mean of *N* observations, where *N* represents the number of independent experiments or cells, respectively. The Kruskal--Wallis test, Dunn's posthoc test, or Mann--Whitney *U*-test was used to determine the nonparametric statistical significance. *P* values less than 0.05 were considered significant. The statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).

The dependence of the changes in \[Ca^2+^\]~i~ on each pharmacological agent was determined by fitting the data to the following function with Origin 8.5 (OriginLab Corporation, Northampton, MA, USA): $$F/F_{0} = \left\lbrack {\left( {F/F_{\text{0int}} - F/F_{0\text{fin}}} \right)/\left( {1 + \left( {{\lbrack x\rbrack}_{\text{o}}/K} \right)} \right)} \right\rbrack + F/F_{0\text{fin}}$$

where *K* is the equilibrium binding constant, \[x\]*~o~* indicates the applied concentration of the pharmacological agents, and *F/F*~0int~ and *F/F*~0fin~ are the initial and final *F/F*~0~ responses, respectively.

Results {#s3}
=======

Immunolocalization of BK Receptors in TG Neurons {#s3-1}
------------------------------------------------

The cultured TG neurons showed positive immunoreactivity to a neuronal marker cocktail (Neuro-Chrom^TM^ pan-neuronal marker), which contained mouse anti-NeuN, anti-MAP2, and anti-βIII tubulin antibodies (Figures [1A,D](#F1){ref-type="fig"}). Intense B~2~ receptor immunoreactivity was observed in primary cultured TG neurons (Figure [1E](#F1){ref-type="fig"}), and it showed colocalization with the pan neuronal marker (Figure [1F](#F1){ref-type="fig"}) in somata, dendrites, axons, and perinuclear regions. Weak but positive B~1~ receptor immunoreactivity was also observed in primary cultured TG cells (Figure [1B](#F1){ref-type="fig"}), and the immunoreactivity colocalized with the pan neuronal marker (Figure [1C](#F1){ref-type="fig"}).

![**Immunolocalization of B~1~ and B~2~ receptors in primary cultured trigeminal ganglion (TG) neurons and TG cryosections. (A,D,G,J)** Cells positive for the pan neuronal marker in primary cultured TG neurons **(A,D)** and TG cryosections **(G,J). (B,H)** Immunoreactivity to the B~1~ receptor antibody (green) in primary cultured TG neurons **(B)** and TG cryosections **(H). (C,I)** Triple immunofluorescence staining with antibodies against the pan neuronal marker (red) and B~1~ receptor (green) in primary cultured TG neurons **(C)** and TG cryosections **(I)**. Nuclei are shown in blue. **(E,K)** Positive immunoreactivity to the B~2~ receptor antibody (green) in primary cultured TG neurons **(E)** and TG cryosections **(K). (F,L)** Triple immunofluorescence staining with antibodies against the pan neuronal marker (red) and B~2~ receptor (green) in primary cultured TG neurons **(F)** and TG cryosections **(L)**. Nuclei are shown in blue. Scale bars are 50 μm in **(A--F)**, and 20 μm in **(G--L)**. Each set of images showing representative immunolocalization of B~1~ **(A--C)** and B~2~ receptors **(D--F)** in primary cultured TG neurons was obtained from six different rats, while that showing immunolocalization of B~1~ **(G--I)** and B~2~ receptors **(J--L)** in TG cryosections was obtained from five different rats.](fncel-09-00229-g0001){#F1}

In the TG cryosections, we could observe positive immunoreactivity against the neuronal marker cocktail (Figures [1G,J](#F1){ref-type="fig"}). These TG neurons in the cryosections showed positive immunoreactivity to the B~2~ receptor antibody (Figure [1K](#F1){ref-type="fig"}), showing colocalization with the pan neuronal marker (Figure [1L](#F1){ref-type="fig"}) in somata, dendrites, axons, and perinuclear regions. However, the TG cryosections did not show B~1~ receptor immunoreactivity (Figures [1H,I](#F1){ref-type="fig"}). Positive immunoreactivity was also observed with NF-H (an A-neuron marker; Figure [2A](#F2){ref-type="fig"}), SP (a peptidergic C-neuron marker; Figure [2D](#F2){ref-type="fig"}), IB4 (a non-peptidergic C-neuron marker; Figure [2G](#F2){ref-type="fig"}), and high-affinity NGF receptor (TrkA; an NGF-responsive nociceptor marker; Figure [2J](#F2){ref-type="fig"}) antibodies. These immunoreactivities against NF-H, SP, IB4, and TrkA antibodies showed colocalization with those against the B~2~ receptor antibodies (Figures [2B,C,E,F,H,I,K,L](#F2){ref-type="fig"}).

![**Immunolocalization of B~2~ receptors in the soma of TG neurons in cryosections. (A)** Positive immunoreactivity to NF-H as an A-neuron marker in TG neurons (arrowhead). **(B,E,H,K)** B~2~ receptor immunoreactivity (arrowheads). **(C)** Triple immunofluorescence staining with antibodies against B~2~ receptors (green) and NF-H (red). Nuclei are shown in blue. **(D)** Positive immunoreactivity to SP as a peptidergic C-neuron marker in TG neurons (arrowheads). **(F)** Triple staining with antibodies against B~2~ receptors (green) and SP (red). Nuclei are shown in blue. **(G)** Positive immunoreactivity to IB4 as a non-peptidergic C-neuron marker in TG neurons (arrowheads). **(I)** Triple staining with antibodies against B~2~ receptors (red) and IB4 (green). Nuclei are shown in blue. **(J)** Positive immunoreactivity to TrkA as an nerve growth factor (NGF)-responsive nociceptor marker in TG neurons (arrowheads). **(L)** Triple staining with antibodies against B~2~ receptors (green) and TrkA (red). Nuclei are shown in blue. **(M)** No fluorescence was detected in the negative control. Scale bars: 20 μm. Each set of photos showing representative colocalization of B~2~ receptors with NF-H **(A--C)** and SP **(D--F)** was obtained from six different rats. Each set of photos showing representative colocalization of B~2~ receptors with IB4 **(G--I)** and TrkA **(J--L)** was obtained from four different rats.](fncel-09-00229-g0002){#F2}

BK-Induced \[Ca^2+^\]~i~ Increases in TG Neurons {#s3-2}
------------------------------------------------

We observed rapid and transient \[Ca^2+^\]~i~ increases in TG neurons following the administration of five different concentrations of BK (0.01, 0.1, 1.0, 10, and 100 nM) in the presence of external Ca^2+^ (2.0 mM; Figure [3A](#F3){ref-type="fig"}). A semilogarithmic plot (Figure [3B](#F3){ref-type="fig"}) illustrates *F/F*~0~ values as a function of the applied BK concentrations, and the equilibrium-binding constant was the half-maximal 50% effective concentration (EC~50~) of 1.0 nM.

![**Ca^2+^ dependence of extracellular bradykinin (BK)-induced \[Ca^2+^\]~i~ responses in TG neurons. (A)** Examples of transient \[Ca^2+^\]~i~ increases following the application of a series of BK concentrations. In the presence of extracellular Ca^2+^ (2.0 mM; lower white box), the application of BK induced transient \[Ca^2+^\]~i~ increases in a concentration-dependent manner. The concentrations of BK (0.01--100 nM) that were administered are shown in the uppermost white boxes. **(B)** The data points illustrate the *F/F*~0~ values as a function of the applied BK concentration. Each data point represents the mean ± standard error (S.E.) of seven experiments (the numbers in parentheses represent the number of tested cells). The curve on the semilogarithmic scale was fitted according to *Equation 1*, which is described in the text. The upper gray box in **(A)** indicates the timing of the application of the 50 mM KCl solution. The equilibrium binding constant of BK was 1.0 nM.](fncel-09-00229-g0003){#F3}

HOE140, a B~2~ Receptor Antagonist, Inhibited the BK-Induced \[Ca^2+^\]~i~ Increases in TG Neurons {#s3-3}
--------------------------------------------------------------------------------------------------

We examined the BK-induced \[Ca^2+^\]~i~ responses in both the presence and absence of external Ca^2+^. The application of BK (1.0 nM) rapidly increased \[Ca^2+^\]~i~ to a peak *F/F*~0~ value of 1.7 ± 0.03 *F/F*~0~ units in the presence (2.0 mM) of external Ca^2+^ and 1.4 ± 0.03 *F/F*~0~ units in the absence (0 mM) of external Ca^2+^ (Figures [4A,D](#F4){ref-type="fig"}). The amplitudes of the BK-induced \[Ca^2+^\]~i~ increases significantly differed between those in the presence and absence of extracellular Ca^2+^. In the absence of extracellular Ca^2+^, BK (1.0 nM)-induced \[Ca^2+^\]~i~ increases were significantly inhibited by a B~2~ receptor antagonist (100 nM of HOE140) (Figures [4C,D](#F4){ref-type="fig"}) but not by a B~1~ receptor antagonist (1.0 μM of R715) (Figures [4B,D](#F4){ref-type="fig"}).

![**Pharmacological identification of BK receptors in TG neurons. (A)** Examples of transient \[Ca^2+^\]~i~ increases following the administration of 1.0 nM of BK (upper white boxes) with (lower gray boxes) or without (lower white box) extracellular Ca^2+^ (2.0 mM). **(B)** Examples of BK-induced (1.0 nM; upper white boxes) \[Ca^2+^\]~i~ increases with (upper black box) or without R715 in the absence (lower white box) or presence (lower gray boxes) of external Ca^2+^. **(C)** Examples of BK-induced (1.0 nM; upper white boxes) \[Ca^2+^\]~i~ increases with (upper black box) or without HOE140 in the absence (lower white box) or presence (lower gray boxes) of external Ca^2+^. **(A,B,C)** The upper gray boxes indicate the timing of the application of the 50 mM of KCl solution. **(D)** The summary bar graph indicates \[Ca^2+^\]~i~ increases during the first (upper column) and second (second upper column) application of 1.0 nM of BK with external Ca^2+^ (2.0 mM) (gray boxes on the right side). The mean values of the increase in \[Ca^2+^\]~i~ following the first (third upper column) and second (fourth upper column) application of 1.0 nM of BK in the absence of external Ca^2+^ as well as the application of 1.0 nM of BK with 1.0 μM of R715 (fifth upper column) and 100 nM of HOE140 (sixth upper column) in the absence of external Ca^2+^ (white boxes on the right side) are shown. Each column denotes the mean ± S.E. of the indicated (in parentheses) number of experiments. The statistical significance between the columns (shown by solid lines) is indicated by asterisks: \**p* \< 0.05.](fncel-09-00229-g0004){#F4}

The B~1~ Receptor Antagonist R715 did not Affect the BK-Induced \[Ca^2+^\]~i~ Increases {#s3-4}
---------------------------------------------------------------------------------------

The BK-induced (1.0 nM) increases in \[Ca^2+^\]~i~ were not significantly inhibited in TG neurons by the administration of four different concentrations of the B~1~ receptor antagonist (0.001, 0.01, 0.1, and 1.0 μM of R715) in the presence (2.0 mM) of external Ca^2+^ (Figures [5A,B](#F5){ref-type="fig"}).

![**Pharmacological identification of B~1~ receptors in TG neurons. (A)** Examples of BK-induced (1.0 nM; upper white boxes) \[Ca^2+^\]~i~ increases showing insensitivity to R715 (0.001--1.0 μM; upper black boxes) in the presence of external Ca^2+^ (2.0 mM; lower white box). **(B)** The summary bar graph indicates \[Ca^2+^\]~i~ increases following the first (upper column) application of 1.0 nM of BK with external Ca^2+^ (2.0 mM). The mean values for the increases in \[Ca^2+^\]~i~ following the application of 1.0 nM of BK with 0.001 μM (second upper column), 0.01 μM (third upper column), 0.1 μM (fourth upper column), or 1.0 μM (fifth upper column) of R715 in the presence of external Ca^2+^ (white boxes on the right side) are shown. Each column denotes the mean ± S.E. of the indicated (in parentheses) number of experiments. There is no statistical significance between the columns. **(C)** Examples of transient \[Ca^2+^\]~i~ increases following the application of a series of concentrations of Lys-\[Des-Arg^9^\]BK (0.01--100 nM; upper white boxes) in the presence of extracellular Ca^2+^ (2.0 mM; lower white box). **(D)** The data points illustrate the *F/F*~0~ values as a function of the applied concentrations of Lys-\[Des-Arg^9^\]BK. Each data point represents the mean ± S.E. of six independent experiments (the numbers in parentheses represent the number of tested cells). The curve on the semilogarithmic scale was fitted according to *Equation 1*, which is described in the text. The equilibrium-binding constant for Lys-\[Des-Arg^9^\]BK was 0.4 nM. **(E)** Examples of Lys-\[Des-Arg^9^\]BK-induced (10 nM; upper white boxes) \[Ca^2+^\]~i~ increases that were significantly inhibited by 1.0 μM of R715 (upper black box) in the presence of external Ca^2+^ (2.0 mM; lower white box). **(A,C,E)** The application of 50 mM of the KCl solution is shown in the gray boxes. **(F)** Summary bar graph of the \[Ca^2+^\]~i~ increases following 10 nM of Lys-\[Des-Arg^9^\]BK with (lower black column) or without (upper white column) 1.0 μM of R715. Each column denotes the mean ± S.E. of the indicated number (in parentheses) of independent experiments. The statistical significance between the columns (shown by solid lines) is indicated by asterisks: \**p* \< 0.05.](fncel-09-00229-g0005){#F5}

Pharmacological Identification of B~1~ Receptors in TG Neurons {#s3-5}
--------------------------------------------------------------

We investigated the \[Ca^2+^\]~i~ increases during the administration of Lys-\[Des-Arg^9^\]BK, which is an endogenous, potent, and highly selective B~1~ receptor agonist (Talbot et al., [@B31]; More et al., [@B23]). The increases in \[Ca^2+^\]~i~ in the TG neurons were induced by the administration of five different concentrations of Lys-\[Des-Arg^9^\]BK (0.01, 0.1, 1, 10, and 100 nM) in the presence of extracellular Ca^2+^ (2.0 mM) (Figure [5C](#F5){ref-type="fig"}). A semilogarithmic plot (Figure [5D](#F5){ref-type="fig"}) illustrates the *F/F*~0~ values as a function of the applied concentration of Lys-\[Des-Arg^9^\]BK with an equilibrium-binding constant of 0.4 nM. In the presence of extracellular Ca^2+^, the Lys-\[Des-Arg^9^\]BK-induced increase in \[Ca^2+^\]~i~ was significantly inhibited by a B~1~ receptor antagonist (1.0 μM of R715) (Figures [5E,F](#F5){ref-type="fig"}).

Discussion {#s4}
==========

The present study demonstrated the functional expression of BK receptors (B~1~ and B~2~) in TG neurons. B~2~ receptors were present on axons and dendrites in A-neurons, non-peptidergic C-neurons, peptidergic C-neurons, and NGF-responsive nociceptors. While the localization pattern of the B~1~ receptor was not clear in the TG cryosections, weak immunoreactivity for B~1~ receptors was observed in the primary cultured TG neurons. The application of BK activated B~2~ receptors and Lys-\[Des-Arg^9^\]BK activated the B~1~ receptors. B~2~ receptor activation mobilized \[Ca^2+^\]~i~ by releasing Ca^2+^ from internal Ca^2+^ stores with partial Ca^2+^ influx from the extracellular medium.

B~2~ receptors, which are expressed ubiquitously and constitutively in healthy tissues, are essential in the early stages of general pain generation (Hall, [@B12]). The constitutive expression of B~2~ receptors in TG neurons has been studied by reverse transcription-polymerase chain reaction (RT-PCR) analyses (Ceruti et al., [@B6]) and immunocytochemical analyses in cultured TG neurons (Patwardhan et al., [@B25]). Although BK-induced \[Ca^2+^\]~i~ increases have also been reported in TG neurons (Ceruti et al., [@B5], [@B6]), precise functional expression patterns of B~1~ and B~2~ receptors in TG neurons remained unclear. The results of the present study showing the functional expression and localization of B~2~ receptors in TG neurons were in line with the previous results. The results of this study were also in line with the pharmacological properties of BK, which is a potent and endogenous agonist for B~2~ receptors and not B~1~ receptors in the sympathetic neurons of the rat superior cervical ganglion (Babbedge et al., [@B2]) and in Chinese hamster ovary (CHO) cells stably expressing recombinant human B~1~ or B~2~ receptors (Simpson et al., [@B30]). Furthermore, BK has an affinity for B~2~ receptors that is 500 times that for B~1~ receptors (Simpson et al., [@B30]). Therefore, B~2~ receptors are histologically and functionally expressed, and endogenous BK preferentially activates B~2~ receptors in rat TG neurons.

The expression of the B~1~ receptor, which is induced as a result of tissue damage and inflammation, is involved in chronic inflammation or tissue injury (Hall, [@B12]). The observations of the constitutive B~1~ receptor expression in TG and dorsal root ganglion (DRG) neurons have been inconsistent. In DRG neurons, some immunohistochemical studies have reported constitutive B~1~ receptor expression (Ma et al., [@B20]; Wotherspoon and Winter, [@B34]). In contrast, other studies have described that B~1~ receptor activation-induced \[Ca^2+^\]~i~ responses could not be observed in DRG neurons (Brand et al., [@B4]). In TG neurons, an immunohistochemical study has shown the constitutive expression of B~1~ receptors (Ma et al., [@B20]). In contrast, RT-PCR analyses have demonstrated that B~1~ receptor mRNA was barely expressed in intact tissue, while it was weakly expressed in primary cultured TG neurons. In primary cultured TG neurons, the levels of expression of B~1~ receptor mRNA have been reported to depend on the length of the culture period (Ceruti et al., [@B6]). The present immunohistochemical and immunocytochemical results were similar to the previous RT-PCR results; B~1~ receptor immunoreactivity was weakly positive in cultured TG neurons and could not be detected in intact TG tissue. Although few report concerning B~1~ receptor-induced \[Ca^2+^\]~i~ response in TG neurons exist, in the \[Ca^2+^\]~i~ imaging in the present study, the B~1~ receptor agonist, Lys-\[Des-Arg^9^\]BK which is a metabolite of endogenous BK in peripheral tissues (Regoli et al., [@B27]), dose-dependently increased \[Ca^2+^\]~i~ in the presence of extracellular Ca^2+^, and this increase was suppressed by a B~1~ receptor-specific antagonist (Figures [5C--F](#F5){ref-type="fig"}). These results of B~1~ receptor expression in primary cultured TG neurons suggest that the expression of B~1~ receptors is induced in TG neurons by tissue damage and/or inflammation. However, further studies are required to evaluate the expression patterns of B~1~ receptors in native TG neurons.

BK-induced \[Ca^2+^\]~i~ increases were observed in both the presence and absence of extracellular Ca^2+^. However, the amplitudes of the \[Ca^2+^\]~i~ increases in the absence of extracellular Ca^2+^ were significantly smaller (84.9 ± 11.3%, *N* = 161) than those in the presence of Ca^2+^ (100%; Figures [4A,D](#F4){ref-type="fig"}). This indicated that the BK-induced \[Ca^2+^\]~i~ mobilization (by B~2~ receptor activation) was mainly composed of Ca^2+^ release from internal stores with partial Ca^2+^ influx from the extracellular medium. Notably, BK has been reported to activate voltage-dependent Ca^2+^ channels in rat submucosal plexus neurons (Avemary and Diener, [@B1]; Rehn et al., [@B28]), and transient receptor potential cation channel subfamily-V member-1 channels in rat DRG neurons (Ferreira et al., [@B11]; Mistry et al., [@B22]). However, BK-induced Ca^2+^ currents could not be recorded in TG neurons (Kitakoga and Kuba, [@B17]). Although further studies are needed to clarify which Ca^2+^ influx pathways contribute to the BK-induced Ca^2+^ influx in TG neurons, the present results clearly indicate that BK mobilizes \[Ca^2+^\]~i~ through both intracellular Ca^2+^ release and Ca^2+^ influx.

In addition, NGF-TrkA signaling plays important roles in not only the developmental processes of peptidergic nociceptive afferents, but also in the generation of acute and chronic pain state in adults. The signaling also up-regulates B~2~ receptor expression in peptidergic nociceptors (Mantyh et al., [@B21]). Thus, the results showing colocalization of B~2~ receptor and TrkA immunoreactivity in TG neurons strongly support reports describing that the B~2~ receptor mediates inflammatory/neuropathic pain induced by peripheral sensitization in the orofacial region (Chichorro et al., [@B8]; Luiz et al., [@B19]); however, the present results obtained from neonatal rat may not reflect the situation in adults.

In conclusion, B~2~ receptors were expressed constitutively, and their activation induced the mobilization of \[Ca^2+^\]~i~ by releasing Ca^2+^ from intracellular stores with partial Ca^2+^ influx. In contrast, B~1~ receptor expression was faint in cultured TG neurons and absent in neurons in TG cryosections, although a metabolite of endogenous BK elicited \[Ca^2+^\]~i~ increases. These results indicated that both BK and its metabolites activated \[Ca^2+^\]~i~ mobilization in TG neurons through B~2~ and B~1~ receptor activation, respectively.
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